184 related articles for article (PubMed ID: 11041460)
1. Increased levels of serum interleukin-18 in Graves' disease.
Miyauchi S; Matsuura B; Onji M
Thyroid; 2000 Sep; 10(9):815-9. PubMed ID: 11041460
[TBL] [Abstract][Full Text] [Related]
2. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
3. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
4. An elevation of stem cell factor in patients with hyperthyroid Graves' disease.
Yamada T; Sato A; Aizawa T; Ootsuka H; Miyahara Y; Sakai H; Terao A; Onuma S; Ito Y; Kanamori A; Nakamura Y; Tejima E
Thyroid; 1998 Jun; 8(6):499-504. PubMed ID: 9669287
[TBL] [Abstract][Full Text] [Related]
5. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
Inukai T; Takanashi K; Takebayashi K; Fujiwara Y; Tayama K; Takemura Y
Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of serum interleukin-12 in Graves' disease.
Tamaru M; Matsuura B; Onji M
Eur J Endocrinol; 1999 Aug; 141(2):111-6. PubMed ID: 10427152
[TBL] [Abstract][Full Text] [Related]
7. Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.
Romaldini JH; Werner MC; Rodrigues HF; Teixeira VL; Werner RS; Farah CS; Bromberg N
J Endocrinol Invest; 1986 Jun; 9(3):233-8. PubMed ID: 2428860
[TBL] [Abstract][Full Text] [Related]
8. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
Kallner G; Vitols S; Ljunggren JG
J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-18 induces insulin resistance in the hyperthyroid state.
Miyauchi S; Matsuura B; Ueda T; Eguchi T; Tamaru M; Yamamoto S; Miyake T; Furukawa S; Abe M; Hiasa Y; Onji M
Endocr J; 2013; 60(4):449-55. PubMed ID: 23257837
[TBL] [Abstract][Full Text] [Related]
10. Increased serum concentration of interleukin-5 in patients with Graves' disease and Hashimoto's thyroiditis.
Hidaka Y; Okumura M; Shimaoka Y; Takeoka K; Tada H; Amino N
Thyroid; 1998 Mar; 8(3):235-9. PubMed ID: 9545110
[TBL] [Abstract][Full Text] [Related]
11. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.
Mariotti S; Caturegli P; Barbesino G; Marinò M; Del Prete GF; Chiovato L; Tonacchera M; De Carli M; Pinchera A
Clin Endocrinol (Oxf); 1992 Nov; 37(5):415-22. PubMed ID: 1486691
[TBL] [Abstract][Full Text] [Related]
12. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell activity in patients with Graves' disease and Hashimoto's thyroiditis.
Wenzel BE; Chow A; Baur R; Schleusener H; Wall JR
Thyroid; 1998 Nov; 8(11):1019-22. PubMed ID: 9848716
[TBL] [Abstract][Full Text] [Related]
14. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
15. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.
Yamada T; Komiya I; Miyahara Y; Komatsu M; Shima I; Inazawa T; Aizawa T
Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180
[TBL] [Abstract][Full Text] [Related]
16. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease.
Sato A; Takemura Y; Yamada T; Ohtsuka H; Sakai H; Miyahara Y; Aizawa T; Terao A; Onuma S; Junen K; Kanamori A; Nakamura Y; Tejima E; Ito Y; Kamijo K
J Clin Endocrinol Metab; 1999 Oct; 84(10):3602-5. PubMed ID: 10523002
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis.
Kojima N; Sakata S; Nakamura S; Nagai K; Takuno H; Ogawa T; Matsui I; Sarui H; Miura K
J Endocrinol Invest; 1992; 15(7):491-6. PubMed ID: 1447487
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
20. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease.
Escobar-Morreale HF; Serrano-Gotarredona J; Villar LM; García-Robles R; González-Porqué P; Sancho JM; Varela C
Thyroid; 1996 Feb; 6(1):29-36. PubMed ID: 8777381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
